tiprankstipranks
aTyr Pharma (ATYR)
NASDAQ:ATYR
US Market
Want to see ATYR full AI Analyst Report?

aTyr Pharma (ATYR) Stock Forecast & Price Target

2,831 Followers
See the Price Targets and Ratings of:

ATYR Analyst Ratings

Hold
5Ratings
Hold
1 Buy
4 Hold
0 Sell
Based on 5 analysts giving stock ratings to
aTyr
Pharma
in the past 3 months
TipRanks enables you to focus on the analyst rating consensus of all analysts or only the top performers​ in the past 3 months

ATYR Stock 12 Month Forecast

Average Price Target

$7.33
▲(762.75% Upside)
Based on 5 Wall Street analysts offering 12 month price targets for aTyr Pharma in the last 3 months. The average price target is $7.33 with a high forecast of $20.00 and a low forecast of $1.00. The average price target represents a 762.75% change from the last price of $0.85.
{"navigator":{"disabled":true},"exporting":{"enabled":false},"title":{"text":null},"chart":{"height":200,"style":{"fontFamily":"Roboto Flex, -apple-system, BlinkMacSystemFont, Segoe UI, Roboto, Helvetica, Arial, sans-serif, Apple Color Emoji, Segoe UI Emoji, Segoe UI Symbol","fontWeight":"400","color":"#5d5d5e"},"spacingTop":30,"spacingRight":60,"events":null},"yAxis":{"labels":{"style":{"color":"inherit"},"distance":6,"x":-6,"y":-6,"zIndex":1,"map_label_formatter":{"10":"$10","21":"$21","-1":"-$1","4.5":"$4.5","15.5":"$15.5"}},"plotLines":[{"color":"rgba(0,0,0,0)","value":20,"label":{"className":" overflowvisible_force","align":"right","x":60,"y":-10,"text":"<div  class=\"positionrelative hoverZ3 triangleleft-bottom flexccc bgwhite shadowhard-3 border1 borderColorwhite-8 colorwhite-8 px2 lineHeight3 fontWeightsemibold fontSize10 radiismall h_pxsmall35\"> <div class=\"w_pxsmall60 flexccc\">\n  <span style=\"color:#199ca5\">High </span>\n\n  <span style=\"color:#199ca5\">$20.00</span>\n  </div></div>","useHTML":true}},{"color":"rgba(0,0,0,0)","value":7.333333333333333,"label":{"className":" overflowvisible_force","align":"right","x":60,"y":0,"text":"<div  class=\"positionrelative hoverZ3 triangleleft flexccc bgwhite shadowhard-3 border1 borderColorwhite-8 colorwhite-8 px2 lineHeight3 fontWeightsemibold fontSize10 radiismall h_pxsmall35\"> <div class=\"w_pxsmall60 flexccc\">\n  <span style=\"color:#828080\">Average </span>\n\n  <span style=\"color:#828080\">$7.33</span>\n  </div></div>","useHTML":true}},{"color":"rgba(0,0,0,0)","value":1,"label":{"className":" overflowvisible_force","align":"right","x":60,"y":10,"text":"<div  class=\"positionrelative hoverZ3 triangleleft-top flexccc bgwhite shadowhard-3 border1 borderColorwhite-8 colorwhite-8 px2 lineHeight3 fontWeightsemibold fontSize10 radiismall h_pxsmall35\"> <div class=\"w_pxsmall60 flexccc\">\n  <span style=\"color:#912767\">Low </span>\n\n  <span style=\"color:#912767\">$1.00</span>\n  </div></div>","useHTML":true}}],"tickPositions":[-1,4.5,10,15.5,21],"lineColor":"#dddddd","gridLineWidth":1,"gridLineColor":"#dddddd","lineWidth":1,"title":{"text":""}},"plotOptions":{"series":{"states":{"inactive":{"opacity":1}}},"line":{"animation":{"duration":0},"dataLabels":{"allowOverlap":true},"borderWidth":1,"marker":{"enabled":true,"fillColor":"#FFFFFF","radius":3,"lineWidth":2,"symbol":"circle","lineColor":"#828080"}}},"xAxis":{"labels":{"style":{"color":"inherit"},"rotation":0,"map_label_formatter":{"3":"Aug<br/>2025","6":"Nov<br/>2025","9":"Feb<br/>2026","12":"May<br/>2026","25":"May<br/>2027"}},"tickPositions":[3,6,9,12,25],"plotLines":[{"color":"#dddddd","width":1,"value":12},{"color":"#dddddd","width":1,"value":12}],"lineWidth":0,"gridLineWidth":1,"gridLineColor":"#dddddd","tickLength":0},"legend":{"symbolRadius":0,"symbolPadding":4,"symbolHeight":14,"borderWidth":0,"symbolWidth":14,"align":"left","verticalAlign":"bottom","enabled":false},"tooltip":{"backgroundColor":"rgba(0,0,0,0)","useHTML":true,"borderWidth":0,"borderColor":"rgba(0,0,0,0)","padding":0,"shadow":null,"headerFormat":"","footerFormat":"","pointFormat":"<div class=\"flexccc lineHeight2 bgwhite shadow2 px3 py3 radiismall fonth10_semibold\">\n                <span class=\"colorgray-3 mb4\">{point.date:%b %d ,%Y}</span>\n                <span>Analyst Consensus</span>\n                {point.info}\n          </div>\n           </div>"},"credits":{"enabled":false},"accessibility":{"description":""},"responsive":{"rules":[{"chartOptions":{"chart":{"spacing":[0,0,0,0],"margin":[30,60,40,5]},"xAxis":{"tickPositions":[3,12,25.25]},"yAxis":{"labels":{"enabled":false}},"title":{"text":null},"subtitle":{"text":null}},"condition":{"maxWidth":500}}]},"series":[{"lineWidth":2,"dashStyle":"ShortDash","name":"High","type":"line","color":"#199ca5","enableMouseTracking":false,"marker":{"enabled":false},"data":[null,null,null,null,null,null,null,null,null,null,null,null,0.833,2.307384615384615,3.781769230769231,5.256153846153847,6.730538461538462,8.204923076923077,9.679307692307694,11.153692307692308,12.628076923076923,14.102461538461538,15.576846153846153,17.051230769230767,18.525615384615385,{"y":20,"marker":{"fillColor":"#199ca5","lineColor":"#199ca5","enabled":true,"symbol":"circle"}}]},{"lineWidth":2,"dashStyle":"ShortDash","name":"Average","type":"line","color":"#828080","enableMouseTracking":false,"marker":{"enabled":false},"data":[null,null,null,null,null,null,null,null,null,null,null,null,0.833,1.333025641025641,1.8330512820512819,2.3330769230769226,2.833102564102564,3.3331282051282045,3.833153846153846,4.333179487179486,4.833205128205128,5.333230769230768,5.83325641025641,6.333282051282051,6.833307692307692,{"y":7.333333333333333,"marker":{"fillColor":"#828080","lineColor":"#828080","enabled":true,"symbol":"circle"}}]},{"lineWidth":2,"dashStyle":"ShortDash","name":"Low","type":"line","color":"#912767","enableMouseTracking":false,"marker":{"enabled":false},"data":[null,null,null,null,null,null,null,null,null,null,null,null,0.833,0.8458461538461538,0.8586923076923076,0.8715384615384615,0.8843846153846153,0.8972307692307692,0.910076923076923,0.922923076923077,0.9357692307692308,0.9486153846153846,0.9614615384615385,0.9743076923076923,0.9871538461538462,{"y":1,"marker":{"fillColor":"#912767","lineColor":"#912767","enabled":true,"symbol":"circle"}}]},{"type":"line","data":[{"y":3.34,"date":1746057600000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 23,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 0, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":4.75,"date":1748736000000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 20,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 0, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":5.13,"date":1751328000000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 23,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 0, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":4.7,"date":1754006400000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 25,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 0, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":5.65,"date":1756684800000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 17,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 10, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":0.69,"date":1759276800000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 11,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 10, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":0.866,"date":1761955200000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 2,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 12, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":0.741,"date":1764547200000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 1,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 3, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":0.783,"date":1767225600000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 1,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 3, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":0.97,"date":1769904000000,"info":" <span style=\"color:#828080\" class=\"mb3 mt2 fonth8_semibold\"> Hold</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 0,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 2, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#828080","enabled":true,"symbol":"circle"}},{"y":0.99,"date":1772323200000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 1,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 4, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":0.85,"date":1775001600000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 1,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 5, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":0.833,"date":1777593600000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 2,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 7, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"fillColor":"black","lineColor":"black","enabled":true,"symbol":"circle"}},null,null,null,null,null,null,null,null,null,null,null,null],"color":"#0666a7"}]}
Highest Price Target$20.00Average Price Target$7.33Lowest Price Target$1.00
The highest, average, and lowest price target of all analysts. Click on ‘Top Analysts’ to focus on the best performers.

Detailed List of Analyst Forecasts​

Detailed List of Analyst Forecasts​
Analyst Profile
Expert Firm
Price Target
Position
Upside / Downside
Action
Date
Follow
Article
Piper Sandler Analyst forecast on ATYR
Piper Sandler
Piper Sandler
$20
Buy
2252.94%
Upside
Reiterated
05/12/26
Piper Sandler Sticks to Their Buy Rating for aTyr Pharma (ATYR)
H.C. Wainwright Analyst forecast on ATYR
H.C. Wainwright
H.C. Wainwright
Hold
Reiterated
05/12/26
Joseph Pantginis Reiterates Hold Rating as FDA Feedback Refocuses Phase 3 Trial Despite Prior Endpoint Miss
JonesTrading Analyst forecast on ATYR
JonesTrading
JonesTrading
Hold
Reiterated
05/12/26
Boris Peaker Reiterates Hold as Constructive FDA Pathway Is Offset by Long Timelines and Funding Overhang for Efzofitimod Sarcoidosis Program
Wells Fargo Analyst forecast on ATYR
Wells Fargo
Wells Fargo
$1
Hold
17.65%
Upside
Reiterated
05/11/26
aTyr Pharma (ATYR) Receives a Hold from Wells Fargo
RBC Capital Analyst forecast on ATYR
RBC Capital
RBC Capital
$1
Hold
17.65%
Upside
Reiterated
03/05/26
aTyr Pharma (ATYR) Gets a Hold from RBC Capital
Jefferies
Hold
Reiterated
09/30/25
Leerink Partners Remains a Hold on aTyr Pharma (ATYR)
Lucid Capital Analyst forecast on ATYR
Lucid Capital
Lucid Capital
$11$1
Hold
17.65%
Upside
Downgraded
09/15/25
aTyr Pharma downgraded to Neutral from Buy at Lucid CapitalaTyr Pharma downgraded to Neutral from Buy at Lucid Capital
Cantor Fitzgerald Analyst forecast on ATYR
Cantor Fitzgerald
Cantor Fitzgerald
Hold
Downgraded
09/15/25
aTyr Pharma (ATYR) Gets a Buy from Cantor Fitzgerald
Analyst Type
Any
Any
Human Analysts
Ranks
Any
Any
Analyst Rating
Any
Any
Upside/ Downside
Any
Any
Action
Any
Any
Analyst Profile
Expert Firm
Price Target
Position
Upside / Downside
Action
Date
Follow
Article
Piper Sandler Analyst forecast on ATYR
Piper Sandler
Piper Sandler
$20
Buy
2252.94%
Upside
Reiterated
05/12/26
Piper Sandler Sticks to Their Buy Rating for aTyr Pharma (ATYR)
H.C. Wainwright Analyst forecast on ATYR
H.C. Wainwright
H.C. Wainwright
Hold
Reiterated
05/12/26
Joseph Pantginis Reiterates Hold Rating as FDA Feedback Refocuses Phase 3 Trial Despite Prior Endpoint Miss
JonesTrading Analyst forecast on ATYR
JonesTrading
JonesTrading
Hold
Reiterated
05/12/26
Boris Peaker Reiterates Hold as Constructive FDA Pathway Is Offset by Long Timelines and Funding Overhang for Efzofitimod Sarcoidosis Program
Wells Fargo Analyst forecast on ATYR
Wells Fargo
Wells Fargo
$1
Hold
17.65%
Upside
Reiterated
05/11/26
aTyr Pharma (ATYR) Receives a Hold from Wells Fargo
RBC Capital Analyst forecast on ATYR
RBC Capital
RBC Capital
$1
Hold
17.65%
Upside
Reiterated
03/05/26
aTyr Pharma (ATYR) Gets a Hold from RBC Capital
Jefferies
Hold
Reiterated
09/30/25
Leerink Partners Remains a Hold on aTyr Pharma (ATYR)
Lucid Capital Analyst forecast on ATYR
Lucid Capital
Lucid Capital
$11$1
Hold
17.65%
Upside
Downgraded
09/15/25
aTyr Pharma downgraded to Neutral from Buy at Lucid CapitalaTyr Pharma downgraded to Neutral from Buy at Lucid Capital
Cantor Fitzgerald Analyst forecast on ATYR
Cantor Fitzgerald
Cantor Fitzgerald
Hold
Downgraded
09/15/25
aTyr Pharma (ATYR) Gets a Buy from Cantor Fitzgerald
Stocks with the Highest Top Analyst Consensus in the Healthcare Sector
Find stocks in the Healthcare sector that are highly recommended by Top Performing Analysts.

Best Analysts Covering aTyr Pharma

3 Months
xxx
Success Rate
9/14 ratings generated profit
64%
Average Return
+11.69%
Copying xxxxxxxxxxxxxxxxxx
trades and holding each position for 3 Months would result in 64.29% of your transactions generating a profit, with an average return of +11.69% per trade.
1 Year
Yasmeen RahimiPiper Sandler
Success Rate
7/14 ratings generated profit
50%
Average Return
-1.04%
Copying Yasmeen Rahimi's trades and holding each position for 1 Year would result in 50.00% of your transactions generating a profit, with an average return of -1.04% per trade.
2 Years
xxx
Success Rate
3/14 ratings generated profit
21%
Average Return
-32.44%
Copying xxxxxxxxxxxxxxxxxx
trades and holding each position for 2 Years would result in 21.43% of your transactions generating a profit, with an average return of -32.44% per trade.
The Best Analyst Covering tool allows you to follow the analysts who have the best success rates and average returns on a specific stock. Only analysts that gave a Buy or Sell rating on the stock in the past 12 months are eligible for inclusion in this tool. Follow the analysts of your choice to receive real-time updates when they publish a new rating.

ATYR Analyst Recommendation Trends

Rating
Jan 26
Feb 26
Mar 26
Apr 26
May 26
Strong Buy
1
0
1
1
2
Buy
0
0
0
0
0
Hold
3
2
4
5
7
Sell
0
0
0
0
0
Strong Sell
0
0
0
0
0
total
4
2
5
6
9
In the current month, ATYR has received 2 Buy Ratings, 7 Hold Ratings, and 0 Sell Ratings. ATYR average Analyst price target in the past 3 months is 7.33.
Each month's total comprises the sum of three months' worth of ratings.

ATYR Financial Forecast

ATYR Earnings Forecast

Currently, no earnings data available.
Currently, no earnings data available.

ATYR Sales Forecast

Currently, no sales data available.
Currently, no sales data available.

ATYR Stock Forecast FAQ

What is ATYR’s average 12-month price target, according to analysts?
Based on analyst ratings, aTyr Pharma’s 12-month average price target is 7.33.
    What is ATYR’s upside potential, based on the analysts’ average price target?
    aTyr Pharma has 762.75% upside potential, based on the analysts’ average price target.
      Can I see which stocks the top-ranking analysts are rating?
      Yes, go to the Analysts’ Top Stocks tool to see stocks with a Strong Buy or Strong Sell analyst rating consensus, according to the top performers.
        How can I follow the stock ratings of top Wall Street analysts?
        Head over to our Expert Center to see a list of the top 100 Wall Street analysts and follow the analysts of your choice. Visit their profiles for more details about their stock ratings and see how they perform on a stock-by-stock basis.
          Is ATYR a Buy, Sell or Hold?
          aTyr Pharma has a consensus rating of Hold which is based on 1 buy ratings, 4 hold ratings and 0 sell ratings.
            What is aTyr Pharma’s price target?
            The average price target for aTyr Pharma is 7.33. This is based on 5 Wall Streets Analysts 12-month price targets, issued in the past 3 months.
            The highest analyst price target is $20.00 ,the lowest forecast is $1.00. The average price target represents 762.75% Increase from the current price of $0.85.
              What do analysts say about aTyr Pharma?
              aTyr Pharma’s analyst rating consensus is a Hold. This is based on the ratings of 5 Wall Streets Analysts.
                How can I buy shares of ATYR?
                Open a brokerage account, see exclusive account opening deals on our Best Online Brokers page.